Virtual R&D Day
Review of Results from Phase 1b Trial of VYN201 for the Treatment of Vitiligo, Preclinical Data for VYN202 and Development Plans for VYN201 and VYN202 Join us for a virtual R&D Day with VYNE Therapeutics. The event will focus on the therapeutic potential of VYNE’s novel and proprietary InhiBETTM platform of its bromodomain and extra-terminal (BET) inhibitors, which includes a locally administered pan-BD BET inhibitor (VYN201) and an oral BD2-selective BET inhibitor (VYN202). Date: November 9, 2023 Time: 1:30 PM EST Location: Virtual VYNE management will review the final results from the Phase 1b trial for VYN201 in patients with nonsegmental…